title: Aortitis in a patient with psoriatic arthritis.
abstract: Aortitis, inflammation of the aortic tissue, is most commonly caused by vasculitic rheumatic conditions, and less frequently infectious organisms. Involvement of the aorta is well defined in HLA-B27-associated spondyloarthropathies such as long-standing ankylosing spondylitis and Reiter's syndrome. However, unlike other spondyloarthropathies, aortic involvement or true aortitis is not a feature of psoriatic arthritis and has been reported in only a few cases. Herein, we report the case of a 22 year-old woman with psoriatic arthritis who developed descending aortitis while using tumor necrosis factor inhibitors.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, 8.Kat, Besevler, 06500 Ankara, Turkey. dratufan@hotmail.com
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Tufan
authors.forename: M
authors.initials: M
authors.lastname: Engin Tezcan
authors.forename: Arif
authors.initials: A
authors.lastname: Kaya
authors.forename: Rıdvan
authors.initials: R
authors.lastname: Mercan
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Oner
authors.forename: Mehmet Akif
authors.initials: MA
authors.lastname: Ozturk
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D001013:Aorta, Thoracic / Q000473:pathology; D001025:Aortitis / Q000150:complications* / Q000473:pathology; D015535:Arthritis, Psoriatic / Q000150:complications* / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D004351:Drug Resistance; D057915:Drug Substitution; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor; D012074:Remission Induction; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D016572:Cyclosporine; D000069285:Infliximab; D000068800:Etanercept